ReviewFrontiers in microbiology2025
Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Engineering oncolytic adenoviruses (OAds) to treat renal and bladder cancers has advanced rapidly. Leveraging insights into adenovirus biology, the molecular pathology of cancer, and recent progress in tumor immunology, multiple strategies have been developed to enhance the antitumor specificity and overall efficacy of OAds as anticancer therapeutics. Combination with other cancer treatment modalities has shown synergistic effects, further augmenting their therapeutic potential. In this review, we discuss the most recent advances in oncolytic adenovirus designs that tailor this vector platform for the treatment of renal and bladder cancers. We further summarize findings from preclinical animal studies demonstrating tumor suppression by OAds, as well as results from clinical trials evaluating their safety and efficacy in cancer patients. Collectively, the accumulated data highlights the significant potential of engineered oncolytic adenoviruses as a novel therapeutic modality for cancer patients that have limited treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.